Astellas five‑year plan targets record sales and deep cost cuts through 2030

Astellas has unveiled a new five‑year corporate strategy (CSP2026) that aims to achieve record‑high revenue in the mid‑2030s, driven by its pipeline and a portfolio of “Strategic Brands.”

The company targets cumulative cost optimization of 200 billion yen (about $1.3 billion) over the plan period (fiscal 2026–2030), supplementing prior cost‑reduction programs that have already trimmed tens of billions of yen in selling, general and administrative expenses.

Strategic Brands such as PADCEV, IZERVAY, VYLOY, VEOZAH, and XOSPATA are expected to double their sales by fiscal 2030 compared with FY2025, and Astellas plans to start 10+ Phase 3 or pivotal studies by FY2030, underpinning its growth ambitions.

Alongside cost cuts, the plan emphasizes disciplined business development and possible large‑scale acquisitions to manage the loom of the Xtandi patent cliff and protect future revenues.